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Focal segmental glomerulosclerosis (FSGS): A disease of the podocytes?
E. Kemény, M.J. Mihatsch, U. Dürmuller, F. Gudat, Institut für
Pathologie, Base!, Switzerland. Based on light and electron micro-
scopic studies, there is circumstantial evidence that podocytes may be
primarily involved in the development of FSGS. They show swelling,
vacuolization and protein droplets. The primary defect of podocytes is
unknown. In a broad study of the cytoskeleton and attachment proteins
in FSGS, a detailed investigation of integrin distribution was per-
formed. One case of recurrent FSGS developed in renal transplant was
studied by immunofluorescence and PAS using monoclonal antibodies
against a1/31 (TS2/7), a2j31 (P1E6), a3/31 (PIB5), C4l3I (P4G9), a5/31
(PID6), HAR/GP9O (P1G12), 132 (P4H9), 13 (3E1) and a., (vitronectin
receptor) integrins. Normal podocytes expressed a3b1, cr5131 and a,, at
their basal surface. In active FSGS lesions a3 13 and a,, showed
redistribution; staining was observed all over the cell membrane and
also along the intracellular vacuoles. This pattern was similar to that
seen for vimentin. Some injured podocytes also expressed HARIGP9O
and/or showed change in actin distribution. £55131 could not be detected
at the base of podocytes over the lesions with matrix increase.
However, it was occasionally focally expressed at cell-cell contact sites
of podocytes. In advanced sclerosis, podocytes capping the lesions
showed decreased expression of a3/31 and together with a,, the receptors
became polarized to the basal surfaces. HAR/GP9O and a1J31 were
either not expressed, or weakly expressed. In conclusion, the noted
change in integrin expression may be associated with the development
of FSGS. Further studies may show whether this is a primary or a
secondary event.
Characterization, internalization and recycling of the vasopressin
(AVP) receptor in vascular smooth muscle cells (VSMC). V.A. Briner, P.
Tsai, R.W. Schrier, U.C.H.S.C. Renal Division, Denver, Colorado,
and Nephrologie, Universitätsspital Base!, Switzerland. AVP is a
vasoconstrictor hormone which initiates its action after binding to its
receptor on VSMC. The aim of this study was to examine: (1)
characteristics of the AVP receptors on VSMC; (2) AVP-induced
internalization and processing of the AVP-receptor complex; (3) AVP
receptor recycling; and (4) biological activity of the recycled receptor.
3H-AVP binding studies revealed a single class of binding sites in
VSMC (Bmax 1.99 x 10 mol/pg protein; KD 2.15 nmol). AVP binding
was specific, time and temperature dependent and saturable. 3H-AVP (2
x i0 M) could be displaced by unlabeled AVP and V1 antagonist.
Pretreatment of VSMC with V1 antagonist abolished the AVP effect on
cytosolic free Ca2 and Ca2 efflux. Phenylarsine oxide (l0 M)
pretreatment of VSMC prevented 3H-AVP-receptor complex internal-
ization and therefore, loss of AVP binding sites. AVP-receptor complex
internalization was temperature dependent and plateaued at 65% (at
30°C after 30 mm; at 37°C after 20 mm). Recovery of the surface binding
occurred fast (t112 = 15 mm at 21°). The AVP-receptor complex
dissociated in an endosomal compartment. Endosomal processing was
prevented by pretreating VSMC with chloroquine (2 x l0 M) which
increases endosomal pH. Cycloheximide (25 g/ml), a protein synthesis
inhibitor, did not prevent the recovery of AVP binding sites. After
reinsertion of the internalized AVP receptor, a rechallenge with AVP
© 1992 by the International Society of Nephrology
caused a normal rise in Ca2 uptake, suggesting full biological activity
of the recycled receptor. In conclusion: (1) the AVP receptor in VSMC
represents a single class; (2) the AVP-receptor complex internalizes in
a time- and temperature-dependent manner. This process is saturable;
(3) receptor recycling is rapid and requires endosomal-mediated disso-
ciation of the hormone-receptor complex and does not require new
receptor synthesis; (4) the recycled receptor demonstrates normal
biological function. The functional studies suggest that the internaliza-
tion/recycling process is an important component of homologous AVP
receptor desensitization and thus, termination of AVP-effect in VSMC.
Comparison of the effects of bradykinin (BK) and arginine vasopressin
(AVP) on cultured vascular smooth muscle cells (VSMC). V.A. Briner, P.
Tsai, R.W. Schrier, and B.S. Dixon, U.C.H.S.C. Rena! Division,
Denver, Colorado and Nephrologie, Universitatsspital Base!, Switzer-
land. The present in vitro study in rat aortic VSMC compared the
biochemical effects of BK, which acts as a vasodilator in vivo, and AVP
as known in vivo vasoconstrictor. Both BK and AVP were found to
cause a dose-dependent increase in the production of inositol trisphos-
phate [(1P3), control 100%; BK (10—6 M) 162%; AVP (106 M) 216%],
increase in free cytosolic Ca2 [(Ca2)1, BK (10—6 M) 197 10 nM; AVP
(106 M) 376 23 nM] and 45Ca2 efflux [BK (10_6 M) 32.0 1.5%; AVP
(106 M) 43.8 1.0%], consistent with activation of phosphatidylino-
sitol specific phospholipase C. BK and AVP produced similar intracel-
lular pH changes characterized by a transient acidification followed by
a sustained alkalinization. A1F4 increased 1P3 to 281% with no further
effect upon adding either BK or AVP. Pretreatment of VSMC for 24
hours with pertussis toxin (PT, 100 ng/ml) ADP ribosilated G1 proteins
but did not abolish BK- and AVP-stimulated 1P3 release and rise in
[Ca2]. In permeabilized VSMC BK- and AVP-effect was dependent
on the presence of GTPaS. VSMC contracted in response to both
106 M BK and l06 M AVP as assessed by digital imaging analysis.
However, supernatant derived from BK-stimulated cultured endothelial
cells (EC) inhibited AVP- and BK-induced contractile response and
caused relaxation of the VSMC [supernatant + BK (l06 M) 60 7%;
supernatant + AVP (l0_6 M, 58 8%]. The production of the relaxing
substance was not affected by meclofenamate. Therefore, BK-stimu-
lated production of vasodilating prostaglandins is not important in
inhibiting VSMC contraction. In contrast methylen blue, an inhibitor of
soluble guanylate cyclase blocked the relaxing effect of the supernatant.
In summary: (1) In VSMC BK and AVP effects are mediated by a
PT-insensitive G-protein; (2) BK and AVP stimulate PIP2 hydrolysis,
leading to an increase in [Ca2]1 and Ca2 efflux, pH changes and
contraction; (3) BK stimulates EC to release EDRF which blocks the
contractile response of AVP and BK and induces relaxation in VSMC.
In conclusion, in a state of EC damage (as ischemia, atherosclerosis)
BK may lose its dilatory effects and elicit vasoconstrictor action.
Prevention of the hypoxemia-induced renal insufficiency by the angio-
tensin converting enzyme Inhibitor perindoprilat. F. Huet, 0. Grigoras,
J.-B. Gouyon, J.-P. Guignard, Service de Pediatrie, CHUV, Lausanne,
Switzerland. The role of angiotensin II, a potent postglomerular vaso-
constrictor, in hypoxemia-induced renal changes is still controversial.
The acute renal effects of hypoxemia and the ability of perindoprilat, a
converting-enzyme inhibitor, to prevent these effects were assessed in
22 anesthetized-ventilated rabbits. Glomerular filtration rate (GFR) and
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renal blood flow (RBF) were determined by the clearance of inulin and
para-aminohippuric acid, respectively. Each animal acted as its own
control. In 8 untreated rabbits, hypoxemia was associated with a
significant drop in mean blood pressure (MBP) (—12 2%), GFR (—16
3%), RBF (—12 3%) and filtration fraction (FF) (—4 2%), and
with an increase in renal vascular resistance (RVR) (+ 18 5%),
suggesting the occurrence of preglomerular vasoconstriction and post-
glomerular vasodilatation, In 7 normoxemic rabbits, intravenous penn-
doprilat (20 tg/kg) induced an increase in urine flow rate (+17 4%)
and RBF (-i- 18 4%), and a decrease in RVR (—14 3%) without any
change in GFR. In 7 rabbits, perindoprilat prevented the hypoxemia-
induced changes in RBF (+11 3%) and RVR (—11 2%) without
improving MBP. FF decreased significantly (—18 2%), while the drop
in GFR was partially blunted (—7 2%). These results suggest
postglomerular vasodilatation and are best explained by the inhibition
of the angiotensin-mediated efferent vasoconstriction by perindoprilat.
An interaction between angiotensin II and adenosine, another renal
vasoactive mediator, on the preglomerular vascular tone is probable
and presently under investigation. These data confirm a major role for
angiotensin II in the regulation of the renal vasomotricity in physiologic
and hypoxemic conditions and the ability of converting-enzyme inhib-
itors to prevent the drop in RBF induced by acute hypoxemia.
Mesangial glomerulonephritis in rats induced by recombinant human
interleukin-6. B. Ryffel and M.J. Mihatsch, Institute of Pathology,
University Base!, Basel, Switzerland. Interleukin-6 (IL-6) is produced
by a variety of cells (lymphocytes, monocytes, endothelium, fibro-
blasts) and affects multiple targets in the body. IL-6 receptors have
been demonstrated on cells of the immune system, on hematopoietic
progenitors, keratinocytes, hepatocytes and mesangium cells. Recom-
binant human (rh) IL-6 is presently developed for the possible use in
clinical conditions of bone marrow depression. Experimental toxico-
logical studies were performed in mice, rats and monkeys. The main
findings in normal animals were a stimulation of hemopoiesis (throm-
bocytosis, slight leukocytosis), of the immune system (slight hypergam-
maglobulinemia) and an acute phase response. IL-6 was well tolerated
up to a dose of 500 tg/kg s.c. given over four weeks. There was no
evidence of any morphologic changes in the liver and kidneys. In the
rat, immunohistochemical investigations revealed mesangial deposition
of IgG, 1gM and complement C3. Furthermore, rh IL-6 was also
detected in the mesangial depots with both polyclonal and monoclonal
IL-6 antibodies. These mesangial depositions were not associated with
any structural changes at light microscopy. In conclusion, the prelimi-
nary results suggest that rh IL-6 is immunogenic and causes mesangial
glomerulonephritis. Direct demonstration of rh IL-6 binding on receptor
positive mesangial cells and formation of immune complexes is ongo-
ing.
Functional effects of Intrarenal interleukin-1 injection in the rabbit. A.
Pedrotti, B.M. Assael and J.-P. Guignard, Service de Pédiatrie,
Lausanne, Switzerland. There is considerable evidence that endotoxin
acts by the release of various cytokines such as interleukin-l (IL-I) and
tumor necrosis factor (TNF). The specific and direct effects of these
mediators on renal function are not yet fully defined. We have demon-
strated that the systemic acute injection of human recombinant IL-113
(0.5 and 5 ig/kg body wt) in the rabbit can induce a significant increase
in urinary flow rate and sodium excretion, associated with a marked
decrease in systemic MBP and OFR. The acute injection of human
recombinant TNFa at the same doses as IL-i has been shown to
produce similar effects on urine flow rate and sodium excretion. To test
whether the renal response to IL-i is secondary to the systemic action
of IL-l or due to a direct renal effect of this cytokine, we injected
human recombinant IL-l directly into the renal artery. Control rabbits
(N = 9), which after a control period received the vehicle into the left
renal artery, did not show any change in rectal temperature, systemic
MBP and renal parameters during the subsequent observation period (2
hours). IL-l-injected rabbits (N = 10), which received IL-l into the left
renal artery (100 pg), increased rectal temperature to + 0.8°C at the end
of the experiment, while systemic MBP, GFR and RBF remained
stable. Urinary flow rate and FENa were significantly increased in the
left IL-l-injected kidney when compared to the control period of the
same kidney (diuresis:+29.2%, P <0.01; FENa:+50.8%, P <0.05), to
the right kidney of the same animal and to the left vehicle-injected
kidney of the control rabbits. Urinary PGE2 excretion, significantly
increased after systemic IL-i injection, did not change after IL-I
intrarenal injection. Our findings are consistent with a direct renal effect
of IL-i on the tubular reabsorption of sodium and water.
Adrenalectomy decreases lipocortin-I M-RNA and tissue protein con-
tent in rats. B.M. Frey, B. Vishwanath, M. Bradbury, M.F. Da/Iman
and F.J. Frey, Medical Center, University of Berne, Switzerland;
Department of Physiology, UCSF, San Francisco, California, USA.
Clinical evidence suggests that acute withdrawal of chronic glucocorti-
coid therapy with suppression of endogenous cortisol production in
RTX patients is associated with an increased susceptibility to rejection.
Furthermore, experimental and clinical observations revealed an en-
hanced immunological and inflammatory response in glucocorticoid
deficiency. The anti-inflammatory response of pharmacological doses of
glucocorticoids has been tentatively attributed to the induction of
lipocortin-I. In order to elucidate whether glucocorticoid deficiency
causes lipocortin-! down regulation, the expression of lipocortin-I
mRNA and protein was quantified in rats with and without adrenalec-
tomy (ADX). The mRNA of lipocortin-I was quantified by polymerase
chain reaction using a constant amount of a modified lipocortin-I eDNA
transcript as an internal standard. The lipocortin-! mRNA was de-
creased by 56 14% in tissue of ADX rats. This down regulation of
lipocortin-I mRNA was not due to a nonspecific effect of ADX since the
mRNA levels of other proteins (c-fos, c-myc, c-erbAbeta, methallothio-
nein-Il) remained unchanged. The decrease in lipocortin-I mRNA in
ADX rats was reflected by a corresponding decrease in tissue (kidney,
lung, spleen, liver) lipocortin-I protein content as assessed by quanti-
tative Western blot analysis. Thus, ADX causes a decline in lipocortin-I
message and protein, an observation in accordance with the increased
susceptibility to inflammatory reactions in glucocorticoid deficiency.
Change in ouabain sensitivity for Na-K-ATPase in cortical collecting
duct (CCD) from rats with puromycin induced nephrotic syndrome. E.
Feraille, M. Rousselot, B. Vogr, A. Doucet, and H. Favre, Division de
Néphrologie, Hôpital Cantonal Universitaire, Genève, Switzerland,
and College de France, Paris, France. We have previously reported
that rats with puromycin induced nephrotic syndrome (PINS) exhibit an
enhancement of the maximal hydrolytic activity of the Na-K-ATPase in
the CCD which is aldosterone and endogenous ouabain-like material
(EOLM) independent. To investigate the mechanisms responsible for
this change in activity, we measure in rats 7 days after either sham or
puromycin i.p. injection, the maximal Na-K-ATPase hydrolytic activity(Vmax), the ouabain sensitive Rb uptake (Rb uptake), the specific
3H-ouabain binding (0-B), and the sensitivity of the Na-K-ATPase for
ouabain (IC 50 for ouabain) (IC 50) in the CCD and calculated the
enzyme turn-over. Na-K-ATPase activity, ouabaIn sensitive Rb flux
and enzyme turn-over were increased twofold in PINS: PINS vs.
controlN = 6, m SE: 1079 44 vs. 2043 126 pmol mm' h'; 7.4
0.4 vs. 14.4 0.7 pEq ' min ' mm'; 5053 361 vs. 2043 124
cycles min' (P < 0.001), respectively, while apparent specific 3H-
ouabain binding and IC 50 for ouabain were decreased: 9.0 0.6 vs. 6.9
0.7 fmol mm, and 1.98 0.5 vs. 8.5 2.01 . lO M (P <0.05 and
<0.02), respectively. Our conclusions were: Enhanced Na-K-ATPase
hydrolytic activity in PINS expresses a functional switch of the enzyme
with a twofold increase in its turn-over. Decrease in IC 50 0 suggests a
change in a isoforms and could explain the loss of responsiveness to
EOLM.
Osmotic nephrosis connected with ovarian hyperstimulation syndrome.
M. Schmidli, H. Gantenbein, F, W. Reutter, Medizinische Klinik B,
Kantonsspital, St. Gallen, Switzerland. We demonstrate a ease of a
22-year-old woman with ovarian hyperstimulation syndrome (OHS).
This syndrome had developed as a complication of ovulation induction.
The therapy of OHS consisted of relieving punctions of ascites (19.4
liters) and infusions of plasma expanders (22.5 liters of low-molecular-
weight Dextran). Four weeks after beginning this treatment, an oliguric
acute renal failure with a decrease of creatinine clearance (3 mI/mm)
developed. The renal biopsy, which was performed to sustain the
diagnosis, demonstrated an osmotic nephrosis with a marked vacuoliza-
tion and swelling of all tubular cells. The differential diagnosis of the
acute renal failure connected with OHS and the pathophysiological
elements of osmotic nephrosis will be discussed. In conclusion, we
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would like to draw attention to the clinical picture of osmotic nephrosis
after infusions of low-molecular-weight Dextran diminishing during the
last few years. Further applications of low-molecular-weight Dextran in
the treatment of OHS could again lead to an increase of cases of
osmotic nephrosis.
Tuberous sclerosis with bilateral renal angiomyolipoma: A rare indi-
cation for renal replacement therapy. M. Niemczyk, M. Schmidli, F. W.
Reutter, Medizinische Klinik B, Kantonsspital, St. Gallen, Switzerland.
Tuberous sclerosis (TS) is a hamartiosis with autosomal dominant
inheritance, variable expression, and a frequency of l:50'OOO to
l50'OOO. Facial angiofibromas, ungual fibromas or a typical histological
diagnosis of affected organs lead to diagnosis. Up to 80% of patients
with TS have renal angiomyolipomas (AML) leading to hematuria,
intrarenal hemorrhage, compression of normal renal tissue and renal
failure. Case report: In this 23-year-old female, facial angiofibromas and
mental retardation led to the diagnosis of TS at age 14. At age 17, an
abdominal CT was performed because of severe pain. Large renal AML
with massive intra- and perirenal hemorrhage were noted, and unilateral
nephrectomy was performed. At age 22, severe abdominal pain and
massive hematuria recurred. CT demonstrated a huge right kidney due
to AML with central hemorrhagic necrosis. Rapidly progressing renal
failure, uncontrollable hematuria and signs of septic shock necessitated
removal of the remaining kidney. Chronic intermittent hemodialysis
was started. The patient was well and back to work 7 months later.
Discussion: Approximately 50% of patients with renal AML have TS,
and approximately 80% of patients with TS have renal AML. AML
becomes symptomatic in the 3rd to 5th decades. Bilateral AML with
massive compression/replacement of normal renal tissue can cause
renal failure. Bilateral nephrectomy might be necessary because of
otherwise uncontrollable renal hemorrhage. Hemodialysis and trans-
plantation are successfully used as renal replacement therapy. In
asymptomatic patients with TS and renal AML, regular controls (BP,
creatinine, ultrasound) are indicated. Tumor enucleation or arterial
embolization at the proper time might avoid nephrectomy. Renal
complications account for approximately 20% of deaths in TS.
Use of low osmolality contrast medium does not elevate apparent
prevalence of medullary sponge kidneys on excretory urograms. J.M.
Ginaiski, T. Spiegel, Ph. Jaeger, Hôpitaux Universitaires de Lausanne
et Berne, Switzerland. Use of low osmolality contrast medium has been
claimed to elevate artificially the apparent prevalence of medullary
sponge kidneys on excretory urograms. To assess the prevalence of
intrapapillary linear densities as well as of homogeneous papillary
blushes on excretory urograms obtained with a low osmolality contrast
medium, iohexol was used in 300 consecutive adult patients. The group
was comprised of 105 patients with renal stone disease (having either
urinary stone(s) on the excretory urogram or a past history of stone) and
195 patients without current or previous nephrolithiasis. A minimum of
3 linear collections of contrast medium within one papilla was required
to be regarded as positive for the so-called intrapapillary linear densi-
ties. Such densities were present in 4% (N = 12)of the 300 patients, that
is 9.5% (N = 10) of the stone-formers and only 1% (N = 2) of the
non-stone-formers (P < 0.001). These respective prevalences are sim-
ilar to those found with high osmolality contrast medium (amidotri-
zoate) in a previous study, that is, 12% in stone-formers and 1% in
non-stone-formers. Prevalence of homogeneous papillary blushes was
12.7% (N = 38), that is, 9.5% of the stone-formers and 14.3% of the
non-stone-formers (NS). These values are much higher than those (4%)
found on excretory urograms taken with amidotrizoate in our previous
study. In conclusion, intrapapillary linear densities on excretory uro-
grams obtained with a low osmolality contrast medium should be
considered as having the same significance as with a high osmolality
contrast medium, that is, presence of medullary sponge kidney. On the
other hand, homogeneous papillary blushes, prevalence of which is
larger on low than high osmolality contrast medium, seem to lack
clinical significance, at least concerning risk of renal stone disease.
Traumatic rupture of the urinary tract in a patient presenting nephro-
genic diabetes insipidus associated with hydronephrosis and chronic renal
failure. HO. Zender, P. Ruedin, F. Moser, J.-F. Bolle, M. Leski,
Division de Nephrologie, Hôpital Cantonal Universitaire, Genéve,
Switzerland. Nephrogenic diabetes insipidus, an inherited x-linked
(NDI type I) or autosomal dominant (NDI type II) defect in urinary
concentrating ability, is sometimes complicated by hydronephrosis, but
very rarely by chronic renal failure. We report on the case of a
34-year-old Japanese man suffering from NDI, supposed to be of type
II, associated with bilateral hydronephrosis, hydroureters and enlarged
trabeculated bladder without obstruction. He presented also with
chronic renal failure, which was documented for the first time 7 years
prior the present admission. The patient was admitted after a traumatic
rupture of the left urinary tract; such a complication has never been
described so far in NDI. Computerized abdominal tomography revealed
free retro- and intraperitoneal liquid around the left kidney; there was
also an impressive thinning of the renal cortex accompanying hudge
hydronephrosis. Patient was treated successfully by transient perito-
neal and vesical drainages. This review focuses on the very rare
complication of chronic renal failure secondary to hydronephrosis in
cases of NDI. Until now, 32 cases of hydronephrosis associated with
NDI have been reported in the literature; among the 14 cases suffering
of NDI with hydronephrosis but without urinary obstruction, only 4
patients presented with chronic renal failure. We conclude that early
prophylaxis is mandatory for these patients suffering from NDI to
prevent hydronephrosis and the risk of secondary chronic renal failure.
This prophylaxis should be early medical treatment, frequent mictura-
tions and regular urological controls.
Nonamyloidotic librillary glomerulopathy: A case report. F. Zysset,
M. Bringolf, J.P. Wauters, J. Hurlimann, M. Campiche, Institut
universitaire de Pathologie, Division de nephrologie du Centre Hospi-
talier Universitaire Vaudois, Lausanne, Switzerland. A 38-year-old
overweight female presented three months ago with a severe nephrotic
syndrome. Laboratory data: plasma creatinine 110 j.LrnoI/liter, plasma
protein 48 g/liter, proteinuria 10 to 15 g/24 hr, hypogammaglobulinemia,
no urinary gammaglobulins. There was no manifestation of systemic
disease. A kidney biopsy was performed. Light microscopy showed 12
glomeruli with areas suggestive of amyloid which were negative with
Congo red. Immunohistology showed positivity for IgG, 1gM, C'3,
fibrin, kappa and lambda chains, whereas amyloid A, protein P and
prealbumin were negative. Electron microscopy showed bundles of
non-branching fibrils approximately 17 nm thick, mainly located in the
sub-epithelial space and in the mesangial matrix. These fibrils were
reminiscent of amyloid fibrils, but were coarser and larger. No finger-
print structures or significant granular deposits were observed. This
case shows the same features as those described by B.C. Sturgill et al
(Human Pathol 16:220, 1985), and by K. Devaney et a! (Modern Pathol
4:36, 1991). This entity appears to be a primary glomerulopathy distinct
from renal amyloidosis by the negativity of Congo red staining and
immunostaining for amyloid, by its ultrastructural features and its
clinical behavior, since no other organs become involved. Hematuna,
proteinuna often in the nephrotic range, and progressive renal failure
are the most prominent clinical features. Caution should be exercised
before diagnosing amyloidosis in cases with atypical morphological
findings.
Systemic lupus erythematosus. H. Favre, R. Lemoine, P.A. Miescher,
Departments of Medicine and Pathology, Geneva, Switzerland. Forty-
two patients suffering from SLE for a mean duration of 9.8 4.1 years
were treated with a drug combination including cyclosporin A (CsA) at
low doses (3—5 mg/kg/BW) after failure of a conventional therapy to
control the disease without inducing inacceptable side effects. During
the 5.3 1.7 year survey, 7 patients received only steroids and CsA, 13
received the same treatment during the first 1 to 3 years and thereafter
a weekly alternative treatment of CsA/Imuran. Twenty-two were given
a basic treatment of steroids and CsA, on top of which pulse therapies
of short duration (3—4 pulses of either cyclophosphamid, methotrexate
or solumedrol) were added when control of the disease was not
satisfactory. After one year of one of these 3 combinations of drugs, the
disease was under control in all the patients (activity index < 7,
S-creatinine < 150 tmol/liter. U-proteins <0.5 g/d, steroid dosages cut
by 50%). Pilot assays have demonstrated that CsA has to be avoided in
patients with renal failure (5-creat. > 150 jmol/liter) as GFR constantly
drops. This effect is not always fully reversible. Examination of the
renal tissue (2 biopsies at 2 and 5 years and 18 patients or I biopsy at
any time between 2 and 5 years in the 24 remaining patients disclosed
signs of nephrotoxicity in 12 patients (28.5%) CsA arteriolopathy or
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striped fibrosis or both were slight to moderate and not seen in a control
group (SLE patients on conventional treatment). By contrast, focal
interstitial fibrosis in excess of glomerular lesions were seen in 26% of
the patients on CsA, a percentage equal to that observed in the control
group. In conclusion, CsA is useful in the treatment of SLE in
diminishing the need of steroids and contributing to the control of the
disease. Major toxicity is not present if low dose are maintained and
exacerbations of the disease treated by the adjunction of another drug.
However, our results suggest a possible increase in CsA nephrotoxicity
in the presence of cytotoxic agents.
Cyclosporin A affects endogenous puisatile secretion of luteinizing
hormone (LH) in rats. F. Schaefer, I. Rembold-Schuster, U. Waither,
G. Waldherr, 0. Mehls, K. Schärer, University Children's Hospital,
Heidelberg, Germany. Previous studies reported the development of
either hypo- or hypergonadotropic hypogonadism in rats treated with
cyclosporin A (C5A). However, endocrine changes under CsA treat-
ment may be due to changes of renal function, especially when high
doses of CsA are applied. In addition, the discontinuous (pulsatile)
nature of LII release was not considered previously, We therefore
investigated spontaneous LH plasma concentration profiles in adult
male rats with intact gonads (int) or after orchiectomy (orchx) who were
treated with low-dose (10 mg/kg/day) CsA or vehicle (control) over a
two-week period. Blood was obtained at 5 minute intervals by contin-
uous exchange transfusion during a three-hour period. LH was deter-
mined using a rat-LH specific assay. Renal function was evaluated by
an inulin slope clearance technique, and renal histology was examined
after the study. Pulse analysis was performed by the CLUSTER
algorithm. Plasma testosterone levels were similar in (int) CsA and
control rats. Regular LH pulses were detected in all orchx rats and
some CsA-treated mt rats, but not in mt control rats. Mean LH levels
were increased in (both orchx and int) CsA-treated compared to control
rats (P < 0.01). This was due to an augmentation of pulse amplitudes (P
> 0.01), whereas the pulse frequency did not differ between CsA and
control rats. Although no histological changes were noted, inulin
clearance revealed a reduction of GFR in the CsA-treated animals (P>
0.05). Since according to previous studies uremia per se decreases LII
pulse amplitudes in rats, our data indicate a stimulatory effect of
low-dose CsA on pituitary LH release.
Treatment of severe nephrotic syndrome unresponsive to corticoids
with cyclosporin A. H. Heule, M. Schmidli, Altstiitten, and Med. B,
Kantonsspilal, St. Gallen, Switzerland. Fourteen adult patients with
severe corticoid-resistent nephrotic syndrome (NS) were treated with
cyclosporin A (CsA). Six patients (pts) had membranous glomerulone-
phritis (GN), 5 had mesangioproliferative GN, 2 pts had membranopro-
liferative GN and 1 patient had minimal change disease. Proteinuria
ranged from 10.6 to 25.0 g/24 hr. Initially 9 of 14 pts had a normal renal
function (creatinine <130 smoWliter). Under CsA-treatment, 8 pts (5 pts
with membranous GN, 2 pts with membranoproliferative GN and 1 pt
with minimal change disease) showed partial or full remission of NS
with decrease of protemuria from 15.8 to 3.3 g/24 hr and increase of
serum protein from 47 to 60 g/liter after three months. In all 5 pts with
mesangioproliferative GN and in I pt with membranous GN, CsA was
discontinued after 6 to 8 weeks due to unresponsiveness. Seven of 9 pts
with initially normal renal function were responders in contrast to only
I to 5 pts with initially decreased renal function (creatinine 146—375
mol/1iter). In 7 of 8 cases, the remission lasted till now (12—60 months)
and renal function remained stable. One of 8 pts showed secondary
resistance after 2 years; he and all primary non-responders were on
dialysis within 2 years. Interruption or dose reduction of CsA led to
relapse of the NS in 3 of 4 pts. Our conclusions were: Steroid resistant
NS in adults responds well to CsA-treatment in membranous, membra-
noproliferative and minimal change disease, especially in pts with
normal renal function. Most of the responders show CsA dependency.
CsA treatment seems to have a positive influence in maintaining renal
function. CsA has no effect on the NS in mesangioproliferative GN.
Calcineurin phosphatase as a target of cyclophilin-cyclosporine com-
plex: Role for immunosuppression and toxicity. H. Husi, M. Zurini, M.J.
Mihatsch and B. Ryffel, Sandoz Pharma AG, Postfach, Base!, Switzer-
land. Calcineurin, a calcium Ca2 and calmodulin-dependent phos-
phatase, was recently identified as the target of cyclophilin-cyclospo-
rime complex (Cell 66:807—815, 1991). We have previously identified
several cyclosporine binding proteins in lymphoid and non-lymphoid
cells in vivo by photoaffinity labeling technique. Briefly, cells of various
tissue origin were incubated with photoactive cyclosporine derivative,
UV-crosslinked, lysed and separated on SDS-PAGE followed by fluo-
roautoradiography. These investigations revealed in addition to cyclo-
philin A and B several higher molecular weight cyclosporine binding
proteins, such as a 45, a 60 and a 170 K proteins. Using freshly purified
calmodulin, calcineurin, and cyclophilin, we can demonstrate a direct
binding of cyclosporine. In the complex, this binding is calcium-
dependent and is abolished by the calcium chelator EGTA. By infer-
ence we postulate that the 60 K protein identified previously is identical
with calcineurin. Since the 60 K protein is also observed in kidney
tubular cells, we speculate that cyclosporine might exert its renal side
effect also through calcineurin. However, the substrate for the phos-
phatase is presently unknown and might differ for lymphoid and renal
cells.
Partial loss of growth potential in pediatric patients after renal trans-
plantation (ix). M. Osterwalder, E. Leumann, J.P. Guignard, 0.
Oet!iker, and M. Zachmann, Universitdts-Kinderkliniken ZUrich, Lau-
sanne, and Bern, Switzerland. Adult height of pediatric patients treated
by Tx is often diminished. Do such patients loose growth potential even
after Tx? Since data in literature are conflicting, bone maturation was
assessed in an unselected group of 24 children (age <16 years) trans-
planted before 1985 with (cadaver) grafts functioning >3 years. Immu-
nosuppression consisted of prednisone, azathioprine and (in 6) of
cyclosporin A. Bone age (BA) was determined according to Tanner!
Whitehouse, and height was expressed as SDS both for chronologic age
(CA) and for bone age (BA), based on the Zurich longitudinal growth
study. Results: According to CA, height deficit improved in 6, remained
unchanged (± 0.3 SDS) in 7, and worsened (>0.3 SDS) in 11(46%). In
contrast, height deficit according to BA improved in 5, remained
unchanged in only 2, and worsened by >0.3 SDS in 17 (71%). The
average height deficit increased from —2.38 to —2.8 SDS (for CA) and
from —0.75 to —1.84 SDS for BA. Poor growth (according to CA)
paralleled impaired graft function. On the other hand, poor growth
according to bone age, resulting in diminished growth potential, was
seen even with good graft function. This suggests that other factors
(such as, prednisone) adversely affected bone maturation. Conclusions:
Bone maturation proceeded often faster than expected. This resulted in
partial loss of growth potential in the majority of patients with reduction
of expected adult height. Better results are expected with less pred-
nisone, earlier (re)-transplantation and possibly with administration of
growth hormone.
Diagnosis and treatment of patients with progressive renal disease. D.
Kiss, H. Hasslocher, K. Gyr, W. Wegmann, Dialysestation, Med.
Klinik, Kantonsspital, Kantonales Institut für Pathologie, Liestal,
Switzerland. In order to investigate the regional etiologies of end-stage
renal diseases (ESRD) and the performed treatment of chronic renal
disease, we analyzed all patients (pts) admitted to our institution for
renal replacement therapy (RRT) between 1985 to 1990. Fifty-one pts.
(30 women and 21 men) with a mean age of 52 years (18—78) were
admitted for RRT. Only 14 pts (28%) had a confirmed diagnosis by
histology (7) or radiology (7). In 20 pts (39%) diagnosis was based on
anamnestic or clinical findings. Seventeen pts (33%) were admitted
without diagnosis. The various diagnostic groups consisted of: nephro-
sclerosis (2), cystic nephropathy (3), hereditary nephropathy (4), dia-
betic nephropathy (4), pyelonephritis (5), giomerulonephritis (5), anal-
gesic nephropathy (12) and chronic renal failure of unknown etiology
(17). In the 14 pts with a confirmed diagnosis the mean s-creatinine
concentration at time of diagnosis was 260 tmol!liter. A specific
treatment of the renal disease had 7 pts (14%), none of the pts had
protein restriction. Forty-one pts (82%) had hypertension, only 16
(39%) had a sufficient treatment. 44 pts (88%) had hyperphosphatemia,
only 15 pts (34%) were treated with phosphate binders. None of the pts
was investigated or treated for renal osteodystrophy. Twenty-one pts
(42%) had symptomatic renal anemia; only 4 pts (19%) were treated. Six
pts (12%) had no treatment at all. Conclusions: Comparing the results to
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other data (EDTA 1987), there was a very low rate of glomerulonephri-
tis (10% vs. 25%) and a very high rate of analgesic nephropathy (24%
vs. 3%) and chronic renal failure of unknown etiology (34% vs. 15%).
Independent of local differences, the reason might be the low portion of
pts with a proven diagnosis (28%). In a greater part of these cases the
investigations were performed in an advanced stage of the disease. The
quality of treatment seems to be directly dependent of the investiga-
tions. To prevent ESRD or to slow down the progression of renal
disease is only possible by an early diagnosis followed by an optimal
treatment.
Prognostic factors and survival of patients returning to dialysis after a
failed renal transplant. A. Colombi, R.S. Martin, M. Lampe, Renal
Unit, Kantonsspital, Luzern, Switzerland. Numerous reports have
dealt with patient survival and prognostic factors after renal replace-
ment therapy. However, few data exist for patients after a failed renal
transplant. With this purpose, we retrospectively studied 33 consecu-
tive patients (age at beginning of second dialysis treatment 38.8 SEM
2.8 years), who returned to dialysis after a mean transplantation time of
42.8 7.8 months. When both dialysis and second transplantation
outcomes were taken together, actuarial patient survival was 67.3, 53.7
and 34.2% at 1, 3 and 5 years after restarting dialysis, respectively.
There were no differences in plasma urea concentration by the time of
starting both first (Dl) and second (D2) dialysis treatments (38.8 2.6
and 38.7 3.3 mmol/liter, respectively). However, a statistically
significant difference was found between corresponding serum creati-
nines (1104.7 59 and 859.3 53.1 mol/liter, respectively, P <0.05).
Clinical parameters at the initiation of D2 were compared for patients
who died in the first two years of treatment with those who survived
beyond that time. Multivariate analysis failed to reveal any association
with a better prognosis. There were also no significant episodes of
major pathologic conditions at the time the transplant was functioning
between these two groups. The data suggest that survival on combined
dialysis and transplantation is poorer after a failed renal transplant
when compared with patients starting dialysis for the first time. They
also probably indicate that a significant muscle wasting had taken place
by the time of D2 and that no prognostic factors are of help in
recommending of discouraging a renal transplant in regard to long-term
survival.
Is cryoglobulinemia type II due to hepatitis C (HCV) infection? A.
Pechère-Bertschi, L. Perrin, Ph. de Saussure, J.-J. Widmann, E.
Giostra, J.A. Schifferli, Départements de Médecine ci de Pathologic,
Hôpital Cantonal Universitaire, Genève, Switzerland. To see whether
HCV is an etiological agent for cryoglobulinemia type II, we studied 15
successive patients who had IgMk-IgG cryoglobulins. The clinical
presentation included skin lesions in all, nephritis in 8, arthritis and
stroke in 4. Two patients had overt hematological malignancies (myelo-
dysplastic syndrome, lymphoma). The 13 remaining patients had sero-
logical evidence for HCV infection as shown by specific enzyme
immunoassays and immunoblots. F(ab)2 fragments of IgG, purified
from the sera of 4 patients, contained anti-HCV activity, indicating that
the serological reactions were not due to the monoclonal IgMk. RNA
was purified from the sera of 7 patients and hepatitis C sequences were
identified in 5 following reverse transcription and DNA amplification.
Liver histology showed a spectrum ranging from chronic hepatitis to
cirrhosis in the 12 patients who had a liver biopsy. The last patient with
HCV infection had elevated transaminases, and nephritis. He re-
sponded to interferon alpha. Hepatitis C may be the major etiological
agent for cryoglobulinemia type 11.
Exaggerated hypocitraturic response after NH4CL loading in normo
calciuric male idiopathic calcium renal stone formers (NCSF). B. Hess,
L. Villiger, D. Ackermann, Ph. Jaeger, Medizinische und Urologische
Universitatspolikliniken, Inselspital, Bern, Switzerland. Acid loading
(high meat protein diet) is expected to reduce urinary citrate (CIT)
excretion. However, out of 61 recurrent male idiopathic calcium stone
formers, normocalciurics (NCSF, Uca x V < 7.5 nimol/day) tended to
have lower 24-hr CIT (2.6 0.3 mmol/day, mean saM) than
hypercalciurics (HCSF, 3.2 0.2 mniol/day, NS), despite evidence of
lower protein intake in NCSF (Uurca x V 356 19 mmol/d vs. 428 16
in HCSF, P = 0.0053). To solve this apparent contradiction, 2-hr fasting
CIT/creatinine was prospectively measured in 14 male HCSF (age
28—56), 10 male NCSF (age 33—64), and 12 healthy men (N, age 28—58),
both before (pre) and after (post) 3 days on NH4C1 (1 mEq/kg BW per
day, 3 doses, 20 mm before meals) added to their free-choice diet.
Results were as follows (all values mean SEM):
[HCO3]0, U-pH0,
HCSF
NCSF
N
23.1 0.8 ma
23.7 0.9 m
24.3 0.6 maPs
5.13 0.06
5.17 007b
4.94 0.06k'
CIT/Crpr CIT/Cr0 ACIT/Cr (%)
0.20 0.03
0.13 0.02t
0.20 0.02
0.12 0.02
0.05 0.01
0.11 0.02
—35.8 8.8
—56.7 6.4a
—43.5 7.7
a j < 0.05 vs. HCSF
b p < 0.01 vs. N
P < 0.01 vs. NCSF and N
Thus, fasting citraturia decreased by 57% in NCSF but only by 36% in
HCSF (P < 0.05) and 44% in N, despite identical acid loads and blood
HCO3 levels after loading, and despite careful exclusion of patients
with incomplete distal renal tubular acidosis. These data suggest
hypersensitivity of renal CIT response to acid loading in NCSF which
might account for the trend towards relative hypocitraturia often
observed in NCSF vs. HCSF under basal conditions.
Impact of six months overnight peritoneal dialysis with 1% amino acid
solution on body composition in patients with terminal renal failure. 0.
Maurer, H. Saxenhoftr, C. Descoeudres, F.F. Horber, Medizinische
Universitdispoliklinik, Inseispital, Berne, Switzerland. After 8 weeks of
1% amino acid solution as osmotic agent in the dialysate, patients on
continuous peritoneal dialysis (CPD) display improvement in plasma
amino acid concentrations. Whether alteration(s) in body composition
also occur remains controversial. Therefore 19 patients, on CPD for at
least 6 months, were assigned to either receive overnight an amino acid
or a glucose containing dialysate and were investigated using whole
body dual x-ray absorptiometry (Hologic QDR l000''). In patients
receiving glucose (Glu-P, N = 10), total body fat mass increased (+ 1.3
0.46 kg, mean SaM), whereas in patients on amino acids (AA-P; N
= 9), it decreased (—0.59 0.32; P < 0.005, change in fat mass in Glu-P
vs. AA-P). This decrease in fat mass in AA-P was attributable to a
decrease in upper body fat (—0.46 0.19), whereas in Glu-P, it
increased (+ 1.5 0.53, P < 0.005). No change in lower body fat was
observed in either group. As a result, the ratio of upper to lower body
fat decreased in AA-P, whereas it increased in Glu-P (—0.04 0.02 vs.
+0.27 0.13, P < 0.04). Total body lean mass remained stable in both
groups during the six months of study (AA-P: 46.6 2.9 kg vs. 47.0
2.9 kg, Glu-P 50.9 3.0 vs. 49.8 2.1 kg baseline vs. 6 months,
respectively). In AA-P plasma urea concentrations increased from 25
2 to 34 3 mmol/liter (P < 0.05), whereas plasma bicarbonate
concentrations decreased from 26 1 to 19 3 mmol/liter (P <0.05),
changes, which were not observed in Glu-P. Plasma albumin and
transferrin concentrations did not change in either group. Conclusion:
Reduction in the amount of glucose in the peritoneal dialysate and the
addition of amino acids allows upper body fat to decrease by more than
5%. In contrast continuous dialysis with overnight glucose increases
upper body fat by more than 15% in a 6 month period. However, no
changes in protein stores were observed with the addition of amino
acids. Therefore, overnight peritoneal dialysis with amino acids offers
minor advantages to protein-malnourished patients on CPD, but puts
them at risk for metabolic acidosis and high plasma urea levels.
Post-transplant hypophosphatemia, related to muscle phosphate con-
tent as detected by nuclear magnetic resonance spectroscopy (MR). D.
Meier, M. Pons, U. Binswanger, P. Bosiger, Nephrologische Station,
Departement für innere Medizin, Institut für Biomedizinische Technik,
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Universitätsspital Zurich, Switzerland. Ten hypophosphatemic pa-
tients, 4 women and 6 men were studied in the early post-transplant
period while treated by steroids, azathioprine and cyclosporin A using
31P MR. The study was repeated after oral phosphate supplements
during 2 to 3 months. Low serum phosphate (Ps) concentrations of 0.56
0.09 mmol!liter were accompanied by low muscle phosphate (Pm)
content of 30.3 4.9 mmollliter. After supplementation, Ps increased to
0.70 0.15 mmol/liter (P < 0.05); in parallel Pin was improved to 36.2
4.1 mmol/liter (P < 0.05). Ps and Pm were loosely correlated (r =
0.49).Changes of different muscle phosphate fractions during treatment
occurred in a proportional manner. Low muscle phosphate content was
confirmed in hypophosphatemic patients after kidney transplantation.
Oral supplements were successful in ameliorating low Ps and Pm.
Whether low muscle phosphate content might be related to muscle
weakness as observed in these patients and could be corrected by
phosphate supplements awaits elucidation.
Erythropoietin (r-HuEPO) treatment in the rat remnant kidney (RRK):
Role of systemic hypertension and glomerular hemostasis in accelerated
progression of renal failure (PRF). P. Ruedin, R. Lemoine, A. Kanfer,
M. Leski, Division de Néphrologie et Départernent de Pathologie,
Hôpital Cantonal Universitaire, Genève, Switzerland and Service de
Néphrologie et INSERM U64, Hôpital Tenon, Paris, France. It was
shown that normalization of hematocrit accelerates the PRF in RRK
due to further aggravation of systemic and glomerular hypertension. To
elucidate the role of systemic hypertension and the possible changes in
glomerular hemostasis, Sprague-Dawley rats with 3/4 surgical nephrec-
tomy were treated either with r-HuEPO 25 U twice a week intraperi-
toneally (group B, D) or vehicle (A, C); groups C and D received
antihypertensive drugs (AHD) (hydrochlorothiazide, reserpine and
hydralazine) in tap water. After 6 weeks, hematocrit, systolic blood
pressure (SBP) and creatinine clearance were measured; glomerular
abnormalities were scored in % of normal glomeruli. Glomerular
procoagulant and fibrinolytic activities (GPCA and GFA) were assessed
on isolated glomeruli.
N =15
for each group
r-HuEPO/AHD
(Results: A B C D
mean SEM) —/— +/— —/+ +1+
Hematocrit, 46 1 52 ia 44 lal 53 lac
vol %
SBP,mmHg 145±4 165±5a 11g3a.b 1133a.b
Creatinine 208 13 163 ioa 223 6" 208 11b
clearance,
pJ/min/100 g
body wt
Glomeruli 2.3 1.0 8.2 l.9 1.7 0.9" 1.9 1.0"
with fibrin
deposits, %
Glomeruli with 5.3 2.1 8.3 1.4 1.5 09b 1.1 0.5"
sclerosis, %
GPCA, 147 3 166 24 108 14' 182 16
tissue factor
units/mg
glom. protein(N=8)
GFA, jig 5.5 0.5 6.1 0.7 3.0 O.6 1.9 02a.b
fibrin lysed/
mg glom.
protein(N =8)
P values: aP < 0.01 vs. group A; b P < 0.01 vs. group B; C < 0.01
vs. group C
This study confirms that correction of anemia with r-HuEPO acceler-
ates the PRF in the RRK. This worsening is mainly related to higher
systemic hypertension since the AHD used, which do not alleviate
glomerular hypertension in this model, prevent completely the aggra-
vation of PRF. Changes in glomerular hemostasis does not seem to play
a role in this model even if GPCA was positively correlated with
hematocrit (r = 0.46; P < 0.01). Consequently, special attention should
be paid to hypertensive predialysis patients treated with r-HuEPO.
Acute hypobaric exposure for stimulation of serum erythropoietin
(EPO) in renal patients and normal controls. J. Quick, U. Binswanger,
B. Schenk, Nephrologische Station, Department für Innere Medizin,
Universitatsspital Zurich, Switzerland. Six patients suffering from
advanced renal insufficiency (Cr 545—1264 smol/liter, 3 on hemodialy-
sis) and 10 normal volunteers were studied at 722 mm Hg atmospheric
pressure (470 m above sea level) and after 3.5 hours of decompression
at 427 mm Hg (4500 m above sea level). Serum EPO levels estimated by
ELISA (Medac, Hamburg) were as follows:
EPO, mU/mI Controls Patients
Basal 11.1 2.0 11.4 4.6
Final 22.8 9.1 12.3 5.2
a P < 0.005, paired t-test
Similar basal EPO concentrations were observed for controls and
patients which, considering the concomitant anemia in the latter, is
inappropriately low. Hypobaric exposure led to a 100% increase in
serum EPO levels in controls but not in renal patients. Maximal
activation of EPO production or disturbed oxygen sensing may explain
these findings in renal failure patients.
Serum erythropoietin (EPO) concentration: Relationship to acidosis?
U. Binswanger, J. Quick, R. Krapf, Nephrologische Station, Departe-
ment Innere Medizin, Universitatsspital Zurich, Medizinische Klinik,
Universitatsspital Bern, Switzerland. Absolute serum EPO concentra-
tions are similar in renal insufficient and normal control individuals, but
inadequate for the concomitant low hematocrit in renal disease. Great
variations are observed in basal EPO levels as well as in the dosage of
exogenous EPO needed for control of renal anemia. The acid-base
status was claimed to be of importance for maintenance of serum EPO
levels. This study investigates serum EPO concentrations in volunteers
with normal kidney function either eating a standardized diet (plasma
[HCO31 = 25.2 0.4 mmol/liter) or ingesting the same diet supple-
mented by ammonium chloride (4.2 mmollkg EW/day) in order to
induce acidosis (plasma [HCO31 = 12.0 0.5 mmol/liter). Basal EPO
levels obtained by ELISA at 450 m above sea (P02 = 150 mm Hg) are
compared with those obtained after a 2 day residence at high altitude
(3500 m above sea level, P02 = 104 mm Hg). Results are as follows (M
SE, mUIml):
acidotic(N = 5)
control(N = 4) pairedt-test
Basal 450 m 16.9 1.6 17.8 1.8 NS
Stimulated 3500m 23.9 2.8 25.1 3.1 NS
percent increase 42.4 11.8 42.0 12.3 NS
Conclusions: NH4C1-induced acidosis does not influence basal and
stimulated serum EPO levels as observed after hypoxic stress in
subjects with normal renal function. Systemic acid-base status may not
be a critical determinant of both steady-state FF0 concentration in
CRF nor of EPO requirements in the therapy of renal anemia.
Erythropoletln (EPO) response and hippuric acid (HA) accumulation.
A. Knoflach, U. Binswanger, Nephrologische Station, Departement fur
Innere Medizin, Universitatsspital Zurich, Switzerland. Variable EPO
dosage for maintenance of near normal hematocrits are required in
dialysis patients suggesting inhibitory factors to influence bone marrow
sensitivity. Ten patients on steady state hemodialysis (HD) and 11
patients on continuous ambulatory peritoneal dialysis (CAPD) exhibit.
ing adequate dialysis indices, ferritin >100 jig/mI, transferrin saturation
>20% and low serum aluminium levels were documented with mean or
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steady state serum hippuric acid concentration as obtained by reversed
HPLC technique. Results are as follows (M SE):
HD
N=10
CAPD
N=1l
Hct 30.8 0.8 31.9 1.5
EPO dosage, U/week/kg 62.7 18.2 66.6 17.6
Serum EPO, jsU/ml (normal 7—20) 15.0 2.8 17.0 1.9
Hippuric acid, mol/liter 173.4 34.2 70.4 21.2a
Urea, mmol/liter 19.1 1.4 17.9 1.5
Creatinine, p.mol/liter 700.1 62.4 667.3 57.8
a P < 0.02 HD vs. CAPD
Correlation studies for the two groups of patients revealed the follow-
ing: serum EPO-HA r = 0.93, P <0.001; and r = 0.72, P <0.01 for HD
and CAPD patients, respectively. No relationship between blood urea
and creatinine concentrations and EPO as well as HA was documented.
Serum HA is considered to reflect uremic toxicity related to therapeutic
EPO response in dialysis patients.
Comparison of efficacy and tolerance of recombinant human erythro-
poietin with intravenous and subcutaneous routes in chronic hemodialysis
patients: A prospective multicentric study. P. Ruedin et M. Leski,
Division de Nephrologie, HOpital Cantonal Universitaire, Genéve,
Switzerland. Although therapy of renal anemia with recombinant hu-
man erythropoietin is now widely established, there is still some debate
about dosage economy when treatment is given by subcutaneous route
rather than intravenously. Effectively, the dosage reduction found on
subcutaneous administration has been contested both in chronic hemo-
dialysis and continuous ambulatory peritoneal dialysis patients. All
these recent studies concerned only a small number of subjects.
Moreover, there is a lack of information about tolerance of the
subcutaneous injections. To clarify these points, efficacy and tolerance
of intravenous and subcutaneous administrations of rHuEPO have been
compared in 50 chronic hemodialysis patients. A 2 months course of
intravenous r-HuEPO, given at stable dosage, was followed by a 6
months course of subcutaneous rHuEPO. rHuEPO dosage was reduced
by 50% when starting subcutaneous administration; subsequently, the
dosage of rHuEPO was regularly adapted to achieve hematocrit levels
between 30 and 35%. At the end of the study, mean rHuEPO dosage
was 82 8 (mean SEM) lU/kg/week, which represented 70 7% of
intravenous rHuEPO dosage. Mean hematocrit value was 32.9 0.5%
when starting subcutaneous administration and also at the end of this
study. Arterial blood pressure remained stable over the whole trial
period as did most biological blood tests which were not influenced by
the route of administration. In 98% of cases, patients expressed either
pain-free (50%) or slight to moderate pain (48%) at the injection site.
This trial confirms a substantial dosage economy when using rHuEPO
by subcutaneous route rather than by intravenous route in patients on
chronic hemodialysis. Moreover, objective and subjective tolerance
was excellent on rHuEPO subcutaneous administration.
Should erythropoietin be given subcutaneously once or three times per
week? J.-G. Pannatier, G. Fellay, and J.-P. Wauters, Division de
Nephrologie, Centre Hospitalier Universitaire Vaudois, Lausanne,
Switzerland, and Centre d'Hémodialyse, Hôpital Cantonal, Fribourg,
Switzerland. Despite the fact that the efficacy of human recombinant
erythropoietin (EPO) as therapy for the anemia of chronic kidney
failure is now well established, mode and frequency of EPO adminis-
tration remains a matter of debate. Previous studies in our unit showed
that subcutaneous instead of intravenous administration allowed to
save up to 30% of the dose needed intravenously to maintain a stable
hematocrit level. The aim of the present study was to evaluate the
possibility to give EPO in one single subcutaneous dose per week while
keeping a target hematocrit level between 30% and 35%. Eighteen
stable chronic hemodialysis patients were included. They all had been
treated previously by subcutaneous EPO 3 times per week. Target
hematocrit had been reached more than 2 months before the start of the
once weekly administration of EPO. The evolution of hematocrit levels
and the total EPO doses administered per week are given below.
Week —8 —4 0 +4 +8 +12 +16 +20 +24
EPO mean 122 129 121 97 97 114 131 125 137
U/kg/w median 110.5 110.5 112.5 107.5 112.5 138 145.5 126 149
Ht% mean
median
32
32
32
32
33
32
32
31
32
31.5
31
30.5
31
30.5
32
31
32
31
All patients tolerated the injections well and the results show that one
weekly subcutaneous administration of EPO is feasible. Hematocrit
levels were well maintained but the EPO doses were significantly
increased after 12 weeks. This increment during the last weeks was
probably due to a drop of the available iron stores which required
parenteral iron supplementation. In addition, there is a possible over-
shoot for some patients during the first weeks.
A system allowing the measurement of mass transfer during hemodi-
alysis. G. Fellay, J.P. Gabriel, (Intr. by Prof. A.U. Binswanger),
Hôpital Cantonal, Fribourg, Switzerland. In recent years, mathemati-
cal modeling in dialysis arose as a consequence of the achievement of
individualized therapies. Two distinct models were used in our center,
namely the urea kinetic model (UK) and the direct dialysis quantifica-
tion (DDQ) for the estimation of the urea distribution volume (V) and
urea generation rate (G). It turned out that, for the same patient, they
provided us with different results. Our theoretical and experimental
investigations of this problem led us to focus our attention on the urea
output during hemodialysis. We came to the conclusion that DDQ was
better than UK with regard to our estimation problem. Unfortunately,
DDQ requires the knowledge of the total of urea removed from the
body. This operation is inconvenient in a clinical context because it
implies the collection of the whole dialysate (80—150 liters). In a
collaboration with Ciposa Microtechniques S.A., we devised a system
allowing the collection of a representative fraction of the latter and
therefore an easy measurement of the urea output. The system has been
tested in our center and proved to be very satisfactory. Our method also
makes possible accurate measurement of mass transfer of other impor-
tant solutes such as sodium, potassium, phosphate, etc., during dialy-
sis. These determinations are at present made by using clearances, but,
because of internal dynamics in the blood itself, reliable measurements
taken in this way are impossible for most of the solutes of interest. Our
system avoids totally these difficulties and provides accurate measure-
ments of mass transfers. It can also be used for precise estimations of
filter qualities in an in vivo situation.
Bone mineral density of lumbar spine, femoral neck and distal tibia in
patients on chronic dialysis. J.J. Mottet, J.P. Casez, M. Picozzi, H.
Saxenhofer, C. Descoeudres, Ph. Jaeger, Medizinische Universitátspo-
liklinik Inselspital, Bern, Switzerland. In 133 dialysis patients (75 men,
58 women), bone mineral density (BMD) was measured using Dual
X-ray absorptiometry (HOLOGIC QDR 1000) at lumbar spine (LS,
mostly trabecular bone), femoral neck (FN, mostly cortical bone),
distal tibial diaphysis (TD, cortical bone) and distal tibial epiphysis (TE,
mostly trabecular bone). Results were expressed as Z-scores (SD from
mean BMD of 643 age and sex-matched controls from Berne). Addi-
tionally, blood was assayed for parathyroid hormone (intact PTH;
Allegro, Nichols Institute) and alkaline phosphatase. Results: table
shows BMD Z-scores (x SEM) of the whole group.
L. spine F. neck T. diaphysis T. epiphysis
Men —0.34 017b —0.80 0.l6a —1.33 0.23a —1.51 0.l7a
Women —0.16 0.17 —0.95 0.l4 —1.30 0.26a —0.75 o.23
a p < 0.0001 vs. control; b p < 0.02 vs. control; C P < 0.01 vs. men
In both sexes, comparison between patients on hemodialysis (HD) and
on chronic ambulatory peritoneal dialysis (CAPD, N = 29) did not
reveal any difference at LS or FN. In contrast at TD, BMD was lower
in HD than in CAPD for men (—1.84 0.24 vs. 0.045 0.34, resp., P
<0.01) as well as for women (—1.76 0.3 vs. 0.12 0.32, resp.,P<
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0.01), but this difference was no longer significant when CAPD and HD
patients were paired for the duration of dialysis. In both sexes, no
correlation could be found between BMD at any site and PTH or
alkaline phosphatase. Discussion: collectively these data show low
BMD at all sites, but demineralization is particularly marked at appen-
dicular skeleton. Higher BMD at lumbar spine than at any other site (P
< 0.01) may be explained by trabecular osteoscierosis due to osteitis
fibrosa. In some cases aortic calcification might have led to overesti-
mation of lumbar BMD.
Etiology of hypercalcemia in chronic hemodialysis patients. D. Kiss,
M.E. Kraenzlin, H.G. Haas, M. Schafroth, A.). Olah, K. Gyr, Dialy-
sestation, Department of Medicine, Kantonsspital Liestal, Endocrine
Practice, Base!, Institute of Anatomy, University of Berne, Switzer-
land. In order to investigate the evolution of renal bone disease and the
development of hypercalcemia, intact parathyroid hormone (i-PTH),
osteocalcin (OC), alkaline phosphatase (AP), S-calcium (CA) and
S-phosphorus (P) were determined regularly during 24 months in 30
chronic hemodialysis patients (HD pts). Hyperphosphatemia was
treated with aluminiumhydroxide (N = 4) and calcitriol (N = 10) or
calciumcarbonate (N = 10) and calcitriol (N = 6). To keep P below 1.6
mmol/liter and CA above 2.2 mmol/liter treatment was adjusted every
month. By this schedule the mean (±so) concentration of i-PTH fell
from 321 70 ng/ml to 135 86 ng/ml. In 15 pts a double tetracycline
labeled bone biopsy was performed. Fourteen pts (46%) developed
hypercalcemia (>2.8 mmollliter). At the start of the study none of the
measured biochemical parameters were significantly different between
the two groups. The distribution of the histologic type of bone disease
was comparable in both groups. At time of hypercalcemia the biochem-
ical bone parameters were significantly lower: i-PTH 83.3 40 vs. 183.6
30 ng/ml, OC 18.8 10 vs. 61.1 14 nglml. P and AP were not
significantly different at time of hypercalcemia. The type and dosage of
the treatment was identical in both groups. Only calcium containing
phosphate binders and/or calcitriol therapy led to a significant suppres-
sion of hyperparathyreoidism and the biochemical bone parameters.
Hypercalcemia occurred only in pts on calcium and/or calcitriol treat-
ment. There was a significant correlation between the suppression of
the biochemical bone parameters and hypercalcemia. Conclusion: The
data suggest that low bone turnover rate and not increased intestinal
calcium absorption is the risk factor most commonly associated with
the development of hypercalcemia under calcium and/or calcitriol
therapy.
Tumoral calcinosis in hemodialysis patients without hyperparathyroid-
ism. H. Freudiger and Z. Glück, Regionaispital, Biel, Switzerland.
Periarticular tumoral calcinosis is a rare complication of chronic renal
failure which has been associated with hyperparathyroidism or elevated
serum 1 ,25(OH)2D levels. We report 6 cases of chronic hemodialysis
patients with tumoral calcinosis and normal levels of immunoreactive
intact parathyroid hormone (iPTH) and low to normal levels of
I ,25(OH)2D: The patients had been on chronic hemodialysis for 5.5
1.1 years (mean saM) when they presented with progressive, inter-
mittently painful periarticular swelling (shoulder: 1; wrist: 4; finger: 2;
knees: 2; neck: 1). Radiographs revealed multiple areas of soft-tissue
calcification, which corresponded to clinically palpable areas. All
patients received at one time aluminum containing phosphate binders.
Laboratory studies showed the following values: serum calcium, lowest
value (lv): 1.98 0.14 mmol/liter, maximal value (my): 2.75 0.10
mmol/liter, phosphate (Iv): 1.91 0.12 mmol/liter (my): 3.27 0.12
mmol/liter alcaline phosphatase: 99 27 lU/liter, C-RP: 71.3 6.4
mg/liter, aluminium: 2.85 0.44 mol/liter, iPTH: 33.7 12.1 pg/mi,
1,25(OH)2D: 16 2 pmol/liter. Chemical analysis of calcified material in
two patients revealed hydroxyapatite crystals. In conclusion, this
report demonstrates that tumoral calcinosis is not necessarily associ-
ated with hyperparathyroidism or elevated I ,25(OH)2 levels, and pro-
vides evidence that hyperphosphatemia by itself might be responsible
for the tumoral calcinosis in chronic hemodialysis patients. Adynamic
bone disease might be responsible for the hyperphosphatemia.
Uncommon manifestations of secondary hyperparathyroidism in pa.
tients on renal replacement therapy. H. Jungb!uth, K. Záruba, Nieren-
station, Stadtspital Waid, Zurich, Switzerland. Secondary hyperpara-
thyroidism (HPT) is a result of chronic renal failure. Bone changes,
bone pain, as well as hypercalcemia are well known to be the conse-
quences requiring parathyroidectomy. We now report 5 patients with
hyperparathyroidism who needed parathyroidectomy because of other
clinical manifestations. Since 1979, 5 patients, aged 42 to 58 years,
undergoing renal replacement therapy (3 HD, 1 CAPD, I with renal
transplant) for several years (5—17), displayed evidence of progressive
myopathy manifested by muscle weakness and easy fatigability. In one
patient only the myocardium was affected, and in another there was
evidence of myopathy, as well as cardiomyopathy. Serum levels for
parathyroid hormone (PTH) were found to be very elevated.
Case
Duration renal
replacement
therapy
Clinical manifestations Laborat
PTH
ory findings
Calciummyo- cardio- arrhy-
No. (years) pathy myopathy thmia pg/mi mmol/liter
1 5 ++ — — 2.57
2 10 + ++ + >2000 2.79
3 17 — + + >2000 2.58
4 9 +++ — — 1100 2.50
5 8 ++ — — >2000 2.59
Subtotal parathyroidectomy was followed by prompt improvement of
muscular and myocardial function. In conclusion, myopathy, as well as
cardiomyopathy, may be the consequence of secondary hyperparathy-
roidism. In spite of lack of hypercalcemia or severe osteopathy,
subtotal parathyroidectomy should be considered in such cases.
Vascular refilling during acetate and bicarbonate dialysis. W. Probst,
D. Schnedifz, J. Zaruba, U. Binswanger, Nephrologische Station,
Departement Innere Medizin, Universitatsspital, Zurich, Switzerland.
The aim of this study was to compare the vascular refilling during
acetate und bicarbonate dialysis. Six patients were each investigated
during an acetate and a bicarbonate dialysis. At the beginning of each
treatment session an ultrafiltration "pulse" was set: the ultrafiltration
volume calculated for 1 hour of the dialysis time was removed during 20
minutes. The relative changes of blood volume were monitored contin-
uously by means of ultrasound velocity. The rate constant of vascular
refilling (Lp) was obtained from the changes of blood volume and of
colloid-osmotic pressure (calculated from plasma protein concentra-
tions) and normalized for 50 kg lean body mass. Values for Lp (ml x
min x mm Hg >< 50 kg' obtained are presented as mean su.
Acetate dialysis
Bicarbonate dialysis
5.69 3.64
5.87 5.48
The difference of the two treatment modalities was not significant
(paired f-test). In spite of great individual variations, no differences of
the vascular refilling can be demonstrated confirming our former clinical
and hemodynamic results. Intravascular volume depletion is an impor-
tant factor for the development of hypotension during hemodialysis
treatment. This factor is not influenced by different refilling from
extravascular compartments during acetate and bicarbonate hemodial-
ysis treatment, respectively.
Activation of the classical pathway of complement by a polyamide
hemodialysis membrane. C. Stoermann, P. Ruedin, M. Pascual, M.
Leski, J. Schiffer!i, Division de Nephrologie, Hdpftal Cantonal Univer-
sitaire, Genève, Switzerland. The various dialysis membranes in use are
bioincompatible, as demonstrated by their capacity to activate the
coagulation and complement cascades. Many of these membranes
activate the alternative pathway of complement and lead to the gener-
ation of C3a, C5a and terminal complement complex (TCC). Whether
the classical pathway can be activated by dialysis membranes remains
not well defined. In favor of a triggering of the classical pathway is the
fact that 0 and C5 fragments are generated very rapidly after initiation
of dialysis and that a patient with classical pathway deficiency has been
shown to generate C3a at the time of dialysis but with a delay of 45
minutes. In a cross-over study involving ten chronic hemodialyzed
patients, we analyzed complement activation induced by two high flux
membranes, polyacrylonitrile (AN 69) and polyamide (PAM), both in
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hollow-fiber configuration. Plasma concentrations of various comple-
ment fragments and complement activation products were measured:
C4d for classical pathway activation, Bb for alternative pathway
activation and iC3b and TCC. With both membranes, there was a
similar and moderate increase in Bb, iC3b and TCC at 15 and 30 minutes
after the onset of dialysis. From basal value, the increase in C4d was
significative at 15 and 30 minutes for PAM (from 4.0 0.6 jg/ml to 4.5
0.7 and 4.6 0.7 g/ml, respectively; P < 0.01) and returned to initial
value after 3 hours (3.6 0.8 ig/ml). Our data suggest that the classical
pathway is activated by PAM membranes, a sequence of events that
might explain better the immediate complement activation induced by
this and possibly other dialysis membranes.
Hemostatic disturbances induced by two hollow-fiber hemodialysis
membranes: Polyamide and polyacrylonitrile. C. Stoermann, P. Ruedin,
P. de Moerloose, G. Reber, M. Leski, Division de Nephrologie et Unite
d'Hémostase, Departement de Médecine, Hôpital Cantonal Universi-
taire, Genève, Switzerland. The effects on hemostasis of two high flux
membranes, polyamide (PAM) and polyacrylonitrile (AN69), both in
hollow-fiber configuration, were analyzed in a cross-over study involv-
ing ten chronic hemodialyzed patients. The wash-out period was one
month. Blood samples were obtained at both arterial and venous sites of
the extracorporeal circuit before dialysis and at 15, 30 and 180 minutes.
Anticoagulation by heparin (as estimated by APTT and anti-FIla chro-
mogenic assay) were similar with either membrane. Primary hemosta-
sis: PAM induced an early significant drop in platelet counts but at 180
minutes there was no more difference between membranes. /3-throm-
boglobulin (/3TG) release by PAM was significantly higher at any time
point. Coagulation: prothrombin activation peptide (Fl + 2) levels were
stable and similar with either membrane. Thrombin-antithrombin III
complexes (TAT) and fibrinopeptide A (FPA) formation was higher
with AN69, although their differences with PAM were not significant.
With both membranes the arterio-venous differences in TAT levels
were negative throughout the session. Fibrinolysis: PAM but not AN69
induced a release of both tissue plasminogen activator (t-PA) and its
inhibitor (PAI-l), but the differences between membranes were not
significant. In conclusion, when primary hemostasis is considered,
PAM seems to be more deleterious than AN69, but inversely coagula-
tion is more activated by AN69. No clear conclusion can be drawn
about their respective effects on the fibrinolytic system.
phosphate were reduced by 63, 56 and 60%, respectively, all P < 0.01)
and well tolerated (no arterial hypotension, nor clinical signs of hypo-
calcemia) despite method-related large ultrafiltration volumes of 3
liters. No bleeding occurred and no significant change in systemic
Lee-White coagulation time, PT!' or thrombin time were encountered
during HD and the following 24 hours. In contrast, Lee-White time was
increased by 150 to 250% (P < 0.05) before and after the dialyzer
compared to peripheral venous blood. Systemic plasma concentrations
of C (mM) were 0.10 0.04 before, 0.52 0.13 after (P < 0.05) and 0.12
0.1 24 hours after HD, resulting in pronounced metabolic alcalosis
after HD (7.53 0.02 vs. 7.41 0.03 before HD and 7.40 0.03 24 hrs
after HD, P < 0.01). In addition, slight hypernatremia (140 4 vs. 144
2 mi, P < 0.03) and an increase in serum parathormon levels (215
265 vs. 360 360 pg/ml, P < 0.05) without change in ionized calcium
were observed following 4 hours of HD. Single-needle HD with
Na3-citrate is an effective method for HD in patients with high risk of
bleeding. The risks of severe hypocalcemia, acute volume overload,
bleeding or extracorporeal blood coagulation seem to be minimal.
Metabolic changes are quickly reversible following acute HD, but
should be carefully reevaluated when C is chronically used for HD.
Calcium acetate as phosphate binder: A 12 month trial in chronic
hemodialysis. J.-G. Pannatier, G. van Melle, and J.-P. Wauters,
Division de Nephrologie, Centre Hospitalier Universitaire vaudois,
Institut universitaire de médecine sociale et preventive, Lausanne,
Switzerland. The control of hyperphosphatemia remains problematic in
uremic patients. The efficacy of the new phosphate binder calcium
acetate was therefore evaluated in patients who remained hyperphos-
phatemic, despite therapy with calcium carbonate and/or Al (OH)3.
Among 71 stable center hemodialyzed patients, all 18 with a phosphate
level regularly l.8 mmol/liter, were considered (8 males and 10
females). Calcium acetate was started as sole phosphate binder at a
dose of 4 g/day. Phosphate, calcium, aluminium and PTH plasma levels
were checked during a 12 month period. The evolution of calcium and
phosphate levels is illustrated below ( SD).
Months —2 —1 0 1
Ca mmol/liter 2.30 0.42 2.33 0.15 2.33 0.24 2.41 0.26
P mmol/liter 1.79 0.35 1.80 0.31 2.08 0.41 1.97 0.43
Assay of guanidines in plasma and urine. M. Bouillie, M. Roth,
Laboratoire Central de Chimie Clinique, Hôpital Cantonal Universi-
taire, Geneva, Switzerland. Guanidines are derivatized by reaction with
benzoin at 100°. This yields fluorescent products which can be sepa-
rated by reverse-phase liquid chromatography and detected with high
sensitivity. The following compounds may be determined in this sys-
tem: methylguanidine, guanidinosuccinic acid, taurocyamine, and
guanidinobutyric acid. These substances accumulate in the plasma of
uremic patients. After dialysis, lower amounts are observed. Two
unidentified chromatographic peaks are also found to occur in much
higher amounts in the blood of uremic patients as compared to healthy
individuals. In view of the toxicity of certain guanidines, this method
may provide an interesting information complementing the results of
traditional tests used for the control of hemodialysis.
Regional citrate anticoagulation using single-needle hemodialysis. J.J.
Mottet, H. Saxenhofer, F.F. Horber, C. Descoeudres, Medizinische
Universitatspoliklinik, Inseispital, Bern, Switzerland. The use of hep-
ann for hemodialysis (HD) in patients (pt) with high risk of bleeding is
contraindicated because of its potent systemic anticoagulant activity.
Extracorporeal, regional anticoagulation with citrate (C) has been
described for this subset of HD patients using dual needle HD. Until
now, single needle HD was contraindicated for extracorporeal dialysis
with C for technical reasons. Therefore a novel technique was devel-
oped and used during a 4-hour HD in 8 patients (3 pt with acute renal
failure and venous blood access and 5 pt on chronic HD with an
AV-fistula). Using two pressure insensitive perfusors, 0.102 M Na3-
citrate was given on the afferent HD-line (800 ml/hr) and 2.5% CaC12 on
the efferent HD-line (120 ml/hr; 7 mg Ca+ +1mm). Blood flow was 350
mI/mm (afferent) resp. 450 mi/mm (efferent). A 1.3 m2 Hemophan
hollow-fiber capillary dialyzer and a dialysate without calcium (flow 500
mi/mm) were used. The HD was effective (plasma urea, creatinine and
Months 2 4 8 12
Ca mmol/liter 2.42 0.21 2.55 0.34 2.39 0,24 2.40 0.34
P mmol/liter 1.80 0.49 1.86 0.35 1.66 0.33 1.55 0.34
The maintenance dose of calcium acetate was 5.82 g/day (4.0—8.0). A
transient hypercalcemia was noted in 8 patients. Aluminum and PTH
levels dropped significantly during the trial. The fact that the hypercal-
cemic episodes were noted almost exclusively during the first months of
the trial suggests that a previous subtle aluminum intoxication pre-
vented bone calcium deposition. This effect was reversed at long term,
allowing adequate plasma calcium and phosphate levels to be obtained.
Calcium acetate appears as an effective, safe and well tolerated phos-
phate binder.
MLC-testing in living related kidney transplantation. D. Garzoni, C.
Goumaz, M. Jeannet, A. Bock, F. Brunner, J. Landmann, G. Thiel,
Division of Nephrology, Department internal Medicine and Surgery,
University Basel; Laboratoire National de Reference pour l'histocom-
patibililé, Hôpital Cantonal Universitaire de Genève, Switzerland.
Whether the degree of lymphocytic stimulation in the mixed lympho-
cyte culture (MLC) has prognostic significance in LRD renal transplan-
tation is not entirely clear. We performed MLC in most of our LRD
grafts done since 1970. Since only 3 of over 60 LRD grafts have been
lost during the first year after grafting, the results of MLC testing could
not be related to the graft failure rate. Instead, we compared MLC
results with the number of rejection episodes (steroid pulses), Pcreat
levels and absence of rejection after withdrawal of all immunosuppres-
sive drugs except CsA. MLC testing was attempted before grafting in 52
donor/recipient pairs. In 13 pairs, the result was inconclusive, due to
technical failure. We were thus left with 39 pairs (19 siblings, 20 parent
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to child), transplanted between 1977 and 1990. MLC results were
graded as negative [stabilized relative response (SRR) <5%], weakly
positive (SRR 5—50%) or strongly positive (SRR> 50%). Results: (1) 10
of 14 (71%) MLC negative patients never needed methyiprednisolone
pulses for suspected rejection in contrast to only 4 of 25 (16%) MLC
positive patients (P < 0.002). (2) 1creat(6 months post-transplant) was
lower (109 37 vs. 141 88 j.Lmol/liter, P < 0.05) in MLC negative
patients. (3) CsA monotherapy was tolerated in 9/14 (64%) MLC
negative vs. 6/19 (32%) MLC positive patients (P < 0.05). (4) No
differences were apparent between weakly positive (14) and strongly
positive (11) pairs. On serological testing, only 10 of the 14 MLC
negative pairs were HLA-A, -B, -DR identical, while the others were
only DR identical (2), compatible (1) and DR half identical (I). in
summary, MLC negativity appears to be predictive of few rejection
episodes, successful CsA monotherapy in the majority and good renal
function. The distinction between weakly and strongly positive MLC
reactions has no prognostic significance. MLC may be negative be-
tween some not completely HLA identical relatives.
Hyperparathyroidism after kidney transplantation: A retrospective
study. J. Vlcek, U. Binswanger, G. Keusch, J. Zdruba, Nephrologische
Station, Departement Innere Medizin, Universitatsspital Zurich, Swit-
zerland. In 534 survivors of 1119 transplanted patients, 32 showed
"persistent" hyperparathyroidism after kidney allotransplantation re-
quiring parathyroidectomy. The frequency of interventions increased
sharply from 0.42 to 4.5 per year with the addition of cyclosporin A as
an immunosuppressive agent. In a case-controlled study, longer dialysis
treatment [mean 54.2 months, (range 9—132) vs. 26.9 (1—72)1; lower
serum inorganic phosphorus concentration 2 months after kidney
grafting [0.65 (0.37—0.98) vs. 0.86 (0.33—480) mmol!literl and higher
mean alkaline phosphatase 2 months prior to parathyroidectomy [157.4
(50—381) vs. 85.2 (27—324) U//liter] were recorded. No differences of
dosage and type of phosphate binders, vitamin D treatment, dialysate
calcium concentration and mode of dialysis treatment (HD vs. CAPD)
between parathyroidectomized and "control" patients were observed.
Since serum creatinine remained stable till time of intervention [130.3
(72—302) vs. 142.7 (68—375) smoI/liter] and did not change thereafter,
the indication seldom is urgent. It was mainly based on persistent and
marked elevated serum calcium and parathyroid hormone levels; addi-
tional causes included elevated alkaline phosphatase as well as bone
pain and pruritus.
Dosage of OKT3 Independent of body weight: A mistake? M. Bacho-
fen, H. Gal/at!, I. Pracht, H. Bock, J. Landmann, G. Thiel, Division of
Nephrology, Department of Internal Medicine and Surgery, University
of Basel; Pharmacology Research Institute, F. Hoffmann-La Roche
Ltd. Basel, Switzerland. OKT3 is administered independently of weight
in fixed doses of 5 or 10mg/day. This obviously contrasts with the usual
regimen of ATG or ALG, which are administered per kilogram of body
weight. We wondered whether light weight patients were thus relatively
overdosed and obese patients underdosed with OKT3. In order to
answer these questions, we measured the OKT3 plasma levels in 36
patients and the ATG plasma levels in 35 patients in a randomized
prospective study. They randomly received 5 mg/day of OKT3 or 4
mg/kg of ATG from the time of operation for 7 consecutive days.
Results: Although OKT3 dosage (range: 0.11—0.05 mg/kg/day) inversely
correlates with body weight in contrast to ATG dosage (range: 4.2—3.0
mg/kg/day), neither OKT3 nor ATO plasma levels show any significant
correlation with body weight. By dividing the patients in two body
weight classes, above and below 70 kg, we can see that there is no
difference in mean or nadir CD3 count (median from day 0—6) in two
weight groups. Furthermore, we could not find a significant difference
in CD3 count at any time after transplantation and also the more rapid
CD3 cell count increase in rejecting patients (not significant) was weight
independent. There was no difference in the number of methyl-pred-
nisolone-pulses given for rejection therapy in the first 30 days after
transplantation and the number of retherapies with OKT3!ATG for
treatment of severe rejections in the two weight groups.
Drug-
plasma
levels CD3 count
Methyl- OKT3/
median median nadir! prednis. ATG-
Group Weight N ng/ml cells/pd jd pulses retherapies
OKT3 <70 kg 18 1478 52 20 26 pulses!
7 pat.
55 17 21 pulses/
7 pat.
96 70 33 pulses!
7 pat.
>70 kg 20 128 96 53 21 pulses!
7 pat.
5
In conclusion, dosage of OKT3 in a fixed dose independent of body
weight (5 mg/day) has no major effect on OKT3 blood levels, CD3
counts nor any negative clinical consequence for the relatively under-
dosed heavy patients.
Microsomal liver function declines steadily after renal transplantation
(RTX). H.J. Schaad, B.M. Frey, E.L. Renner, R. Preisig and F.J. Frey,
Inseispital, University of Berne, Switzerland, We have previously
shown that the functioning hepatocyte mass (galactose elimination
capacity, GEC) and microsomal liver functions (metabolic clearances of
unbound prednisolone, MCR of Po, and of cyclosporin, MCR of CsA)
are impaired I month and 1 year after successful RTX (N 28;
Hepatology 9, 606, 1989). To assess the natural history of these hepatic
functional derangements, we reinvestigated these patients with stable
renal function 3 to 5 years after RTX. GEC remained below that in
healthy controls, but did not change during follow-up. In contrast, the
MCR of Po declined steadily during follow up averaging 4.98 0.71
ml/min x kg at 3 to 5 years (compared to 5.83 1.51 and 6.80 1.73
mi/mm x kg at 1 year and 1 month). These values were lower (P < 0.01)
than those observed in controls (7.56 1.59 mI/mm X kg). The MCR of
CsA decreased similarly with time averaging 4.5 1.2 mI/mm x kg at
3 to 5 years (compared to 4.9 1.2 and 5.9 2.1 mi/mm x kg at 1 year
and 1 month). In conclusion: (I) the functioning hepatocyte mass and
microsomal liver functions are markedly impaired after RTX; (2)
microsomal liver functions, but not the functioning hepatocyte mass,
steadily decline with time during 3 to 5 years after RTX, despite the
absence of clinical and (routine) laboratory evidence of significant liver
disease and excellent graft function.
Segmental redistribution of bone following kidney transplantation. U.
Steiger, F.F. Horber, J.P. Casez, A. Montandon, C. Descoeudres, Ph.
Jaeger, Medizinische Universitãtspoliklinik, Inseispital, Berne, Swit-
zerland. After kidney transplantation (KT), patients (KTP) exhibit
decreased bone mineral density (BMD) of the lumbar spine and
increased fracture rates of ribs and vertebrae. However, the effect of
KT on the other parts of the human skeleton is unknown. To address
this issue, 14 normal healthy volunteers and 14 age, sex and body mass
index matched KTP were examined by whole body dual x-ray absorp-
tiometry (Hologic QDR 1000W) KTP were examined immediately
following KT (11 2 days, mean suM) and then on a monthly basis
up to 5 months. Whole body mineral content was lower in patients
immediately following KT (2.45 0.09 vs. 2.06 0.12 kg hydroxyap-
atite; P < 0.02). Segmental analysis at day 11 revealed that BMD was
lower in KTP in the head (—11.3 1.5%; P < 0.02), arms (—9.7
2.3%, P <0.03), pelvis (—10.6 2.7%, P < 0.02) and legs (—12 2.5%,
P < 0.02), but not in the ribs, thoracic and lumbar spine. Within 154
8 days following KT, BMD progressively decreased in the ribs (—5.2
0.9%, P < 0.001), thoracic spine (—10.2 1.8%, P < 0.02) and pelvis
(—3.8 0.8%,P <0.01), whereas it increased in the legs (+ 1.9 0.7%,
P < 0.02). Overall trabecular bone (ribs, spine and pelvis) decreased by
4.3 1.0% within 120 days. No further decrease was observed during
the fifth month after KT. Scanning the lumbar spine at high resolution
[(N= 11), coefficient of variation (CV) <1%], spine BMD decreased by
2 to 18% (median: 7%) in 154 days (P < 0.001), a change, which could
not be detected by segmental analysis of whole body scan (CV < 5%).
in conclusion, after KT, a redistribution of bone mass occurs from the
>70 kg 18 1205
p.g!ml
ATG <70 kg 15 113
4
2
2
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axial to the appendicular skeleton possibly as a consequence of gluco-
corticoid therapy and hyperparathyroidism. These data provide evi-
dence for early changes in bone skeleton following kidney transplanta-
tion and may provide a rationale for early preventive drug trials.
Fully HLA A/B/DR incompatible cadaveric kidney grafts: A positive
surprise. B. Huser, J. Landmann, F. Brunner, M. Mihatsch, G. Thiel,
Departement innere Medizin and Chirurgie, Institut für Pathologic,
Kantonsspital Base!, Switzerland. A benefit of optimal HLA A/B/DR
matching in cadaveric kidney transplantation has been described in
many studies. In Switzerland, however, the rules for exchanging
kidneys between centers have not precluded transplantation of com-
pletely mismatched kidneys. This report compares the outcome of 33
"incompatible" kidneys (6 serologically proven mismatches of the
HLA A/B/DR antigens, group I) to 46 transplants with at least one
identity (0 or 1 mismatches) per HLA A/B/DR locus (group II) and to 17
transplants with 3 or 4 identities (0 or 1 mismatch) on the HLA B/DR
loci (group III). Only first transplant performed between August 1977
and November 1990 were included and all donors and recipients had to
have two different alleles detected on each of the 3 subloci. Results: No
significant differences were found between age and sex distribution of
recipients, waiting time on dialysis, number of blood transfusions and
peak HLA antibody titer before grafting, warm ischemia time and donor
age. Only cold ischemia time was significantly shorter with a median of
16 hours 45 mm (group I) compared to 21 hrs 34 mm (group II). Patient
survival did not differ with one death during the first year in groups I
and II, no death in group III. Graft survival at one year was 86% in
group I, 88% in group II and 76% in group III. Plasma creatinine and
dosage per body weight of cyclosporine and prednisone (compared at
monthly intervals) did not differ between groups and the proportion of
patients receiving triple therapy with azathioprine was not greater in
group I. The number of solumedrol pulses administered during the first
12 months after grafting was identical in the 3 groups and identical
proportions of patients never needed transplant biopsies or solumedrol
pulses for suspected or proven rejection crisis. Our experience with
completely mismatched cadaveric first transplants is no less satisfac-
tory than with well matched cadaveric kidneys.
Glomerular hyperfiltration after living donor kidney transplantation.
H.A. Bock, M. Bachofen, J. Landmann, G. Thiel, Division of Nephrol-
ogy, Kantonsspital, Base!, Switzerland. Glornerular hyperfiltration is
thought to be a pathogenic factor in the progression of chronic renal
disease. However, there is also hyperfiltration after unilateral nephrec-
tomy, which is of potential concern for living donor kidney transplan-
tation (LDKT). Therefore, we prospectively studied donor and recipi-
ent renal function in LDKT using standard clearance methods. Donor
function was evaluated before uninephrectomy as well as I week and 1
year after. Recipient function was measured 1 month and 1 year after
LDKT. All recipients were taking cyclosporin A (CsA) at the time of
study. Hyperfiltration was calculated as the ratio of 1-kidney inulin
clearance to of the donor's pre-nephrectomy inulin clearance (mean
SaM):
Donor
preNxN 29
Donor
1 wk.
27
Donor
1 yr.
16
Recip.
I mo.
28
Recip.
1 yr.
16
Inulin clearance 104 4 66 3 66 4 54 3 48 4
mI/mm
N with 19/27 12/16 11/28 4/16
hyperfiltration
>10%:
PAH clearance 548 28 358 20 317 17 368 27 239 19
mllmin
N with 21/27 9/16 16/28 3/16
hyperperfusion
>10%:
Urinealbumin 8±1 15±3 13±5 99± 17 177±76
mg/24 hr
Nwith>30 0 2 1 16 8
mg/24 hr
Blood pressure 126/78 126/81 123/82 143/93 134/90
In donors, hyperfiltration after uninephrectomy averaged 128 5%,
hyperperfusion 133 6%. Hyperfiltration or hyperperfusion did not
correlate with donor age (range 22—68 yrs). Microalbuminuria >30
mg/24 hr developed in 3 of the donors, in one of which albumin
excretion later normalized. Albuminuria in donors was unrelated to the
degree of hyperfiltration. No de novo hypertension developed in the
donors. Our conclusions were: (1) Only 3/4 of donors develop hyperfil-
tration after uninephrectomy. (2) Up to 1 year after uninephrectomy,
there is no evidence for hyperfiltration-induced renal damage in LDKT
donors with the possible exception of occasional microalbuminuria. (3)
Hyperfiltration/hyperperfusion occurs with surprising frequency in CsA
treated transplant kidneys.
